Integrated DNA Technologies Launches First Cas9 Enzyme That Drastically Reduces CRISPR Off-Target Effects Without Significant Loss Of On-Target Activity Post author:Sam Post published:July 31, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Bay Area's SutroVax Scores $64 Million To Tackle Pneumococcal Vaccines March 20, 2017 Cellectar Biosciences Further Deepens Intellectual Property Portfolio With Patent Grant For PET Imaging PDC March 20, 2017 RedHill Biopharma To Host Second Quarter 2017 Financial Results Conference Call On July 25, 2017 July 17, 2017
Cellectar Biosciences Further Deepens Intellectual Property Portfolio With Patent Grant For PET Imaging PDC March 20, 2017
RedHill Biopharma To Host Second Quarter 2017 Financial Results Conference Call On July 25, 2017 July 17, 2017